News

The FDA has accepted a supplemental new drug application for sodium oxybate as a treatment for cataplexy and excessive daytime sleepiness in children with narcolepsy.

Given that suicide is increasing as a public health concern, better identification of warning signs could assist in directing preventative strategies to the right people.

The anti-amyloid protofibril antibody achieved statistical significance in its key efficacy endpoints after 18 months.

Which sports-related migraine is associated with longer recovery time, as well as cognitive, neurobehavioral, and somatic symptoms? Test your skills in this quiz.

The autologous stem cell therapy is currently in a phase III trial.

Phase III results have shown galcanezumab is efficacious for multiple headache conditions.

The anti-CGRP treatment continues reducing migraine days a year after patients received infusions.

Rimegepant significantly reduced pain and the most bothersome symptom while showing an "excellent" safety profile for patients with acute migraine attacks.

The intravenous quarterly CGRP inhibitor eptinezumab significantly reduced monthly migraine days compared with placebo for patients with chronic migraine.

We're trying to make our stress tests more realistic.

A retrospective analysis of a dose-ranging trial found that those who were administered 100-mg daily riluzole, in comparison with placebo, spend a longer period of time in stage 4 of ALS.

The FDA had accepted a new drug application for APL-130277, a sublingual film version of apomorphine, as a treatment for OFF episodes in patients with Parkinson disease.

The FDA has approved cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome for patients 2 years of age and older.

A novel gene therapy has demonstrated impressive early results in a small sample of 3 children with Duchenne muscular dystrophy.

Across 3 cohorts, the therapy showed improvements in on-time without troublesome dyskinesia, ranging from 2.1 hours to 3.5 hours.

Nearly a decade in the making, revised guidelines provide 8 key points for effective nonpharmacologic treatment of epilepsy in childhood.

A grant from the National Institute of Neurological Disorders and Stroke, which allows for concurrent phase I and II trial design review, will speed up the development of novel treatments for patients with ALS and FTD.

Those treated with ocrelizumab observed a 46% reduction in their risk of progressing to a wheelchair compared to those administered placebo treatments.

The results of a pair of trials of lemborexant support phase III findings of the investigational sleep-wake regulator.

The FDA has granted a priority review designation to perampanel for 2 potential new indications for pediatric patients with seizures.

What are the key symptoms of TIND, a rare condition that can occur after rapid normalization of blood glucose levels following prolonged periods of hyperglycemia?

How effective is the telemedicine versus telephonic approach in acute care?

New research may help doctors determine when (and when not) to test for antiglutamate decarboxylase antibodies in patients with neurological disorders and psychiatric symptoms.

The FDA has approved the EmboTrap II Revascularization Device for thrombectomy within 8 hours of the appearance of symptoms for patients with ischemic stroke.

The FDA has granted a Breakthrough Therapy and Fast Track Designation to pitolisant for cataplexy in patients with narcolepsy, as Harmony Biosciences prepares a new drug application for the drug.

A new study has found that patients with neuropsychiatric systemic lupus erythematosus have 3 times increased risk of death, and this risk increases to over 7 times higher in patients with focal CNS symptoms.

The first-in-class anti-CGRP monoclonal antibody erenumab has gained FDA approval for the prevention of migraines.

New treatments for MG may have a more direct effect on the action of acetylcholine on the neuromuscular junction than steroids, IVIG, and plasmaphoresis.

The FDA has expanded the indication for fingolimod to include the treatment of children and adolescents age 10 years and older with relapsing multiple sclerosis.

An expanded access program has been opened to allow patients with ALS access to BHV-0223, a sublingual formulation of riluzole, all while Biohaven Pharmaceutical prepares a new drug application for the drug.